Skip to main content

Table 1 Clinical trials investigating venetoclax as single agent in hematological malignancies

From: BCL-2 as therapeutic target for hematological malignancies

Disease(s)

Study phase

Estimated* or actual** enrollment

Register number in clinical trials.gov

NHL (non CLL/SLL/MCL)

I

11**

NCT01969695

R/R CLL after BCRis (ibrutinib or idelalisib)

II

127**

NCT02141282

R/R CLL/SLL and NHL

I

211*

NCT01328626

R/R AML or untreated AML unfit for intensive therapy

II

32**

NCT01994837

R/R or untreated CLL with 17p deletion

II

158**

NCT01889186

R/R CLL

III

250*

NCT02756611

R/R CLL with 17p deletion

II

70*

NCT02966756

R/R CLL

III

200*

NCT02980731

Waldenström Macroglobulinemia

II

33**

NCT02677324

  1. AML acute myelogenous leukemia, BCRi B-cell receptor signaling pathway inhibitors, CLL chronic lymphocytic lymphoma, NHL non-Hodgkin lymphoma, R/R relapsed/refractory, SLL small lymphocytic lymphoma, V venetoclax
  2. Results retrieved from the Clinical Trials database (www.clinicaltrial.gov), accessed at 20 Feb 2018 *Estimated enrollment at the time of Clinical Trials database access. **Actual enrollment at the time of Clinical Trials database access
  3. The following studies were not included in this table: study with status “withdrawn” (NCT02095574); studies on myelodysplasic syndromes, and observational studies (NCT03415035 and NCT03342144)